Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Innovations and Advances in Breast Cancer Research and Treatment
share announcement

Innovations and Advances in Breast Cancer Research and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 25 March 2025 | Viewed by 2687

Special Issue Editor

Dr. Palma Fedele

E-Mail
Guest Editor
Oncology Unit, Dariuo Camberlingo Hospital, Francavilla Fontana, ASL Brindisi, Brindisi, Italy
Interests: breast cancer; translational research; tumors; cancer biology; oncology; chemotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

At present, significant advancements have been made in the field of breast cancer research, leading to improved detection, diagnosis, and treatment options. This Special Issue aims to gather cutting-edge research and innovative developments in breast cancer to further enhance our understanding and management of this complex disease.

The topics of interest for publication include but are not limited to the following:

  • Early detection and diagnosis techniques;
  • Novel therapeutic strategies and drug development;
  • Personalized medicine and targeted therapies;
  • Survivorship and quality of life issues for breast cancer patients;
  • Role of artificial intelligence and machine learning in breast cancer research;
  • Immunotherapy and its applications in breast cancer treatment.

Dr. Palma Fedele
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • early detection
  • genomics
  • personalized medicine
  • targeted therapies
  • survivorship
  • quality of life
  • artificial intelligence
  • machine learning
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1288 KiB  
Article
Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study
by Palma Fedele, Matteo Landriscina, Lucia Moraca, Arianna Gadaleta-Caldarola, Antonio Cusmai, Francesco Giuliani, Vincenzo Chiuri, Francesco Giotta, Antonello Pinto, Valentina Mirisola and Gennaro Gadaleta-Caldarola
J. Clin. Med. 2024, 13(23), 7441; https://doi.org/10.3390/jcm13237441 - 6 Dec 2024
Viewed by 625
Abstract
Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the standard of care for hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in combination with endocrine therapy. However, the real-world efficacy and safety of standard versus reduced doses in [...] Read more.
Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the standard of care for hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in combination with endocrine therapy. However, the real-world efficacy and safety of standard versus reduced doses in elderly patients remain unclear. This study aims to compare the clinical outcomes of standard versus reduced doses of CDK4/6 inhibitors in elderly patients with metastatic breast cancer. Methods: This multicenter retrospective cohort study included 158 patients aged ≥70 years diagnosed with HR+/HER2-negative metastatic breast cancer who received either standard or reduced doses of CDK4/6 inhibitors (Ademaciclib, Ribociclib, Palbociclib) as first-line therapy. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated. PFS and OS were estimated using the Kaplan–Meier method, and comparisons between groups were performed using a log-rank test. Results: Of the total population, 108 patients (68.4%) received the standard dose, and 50 patients (31.6%) received a reduced dose. The standard-dose group had significantly longer median PFS compared to the reduced-dose group (21.3 vs. 15.2 months, p = 0.014), while the median OS did not differ significantly (37.2 vs. 37.2 months, p = 0.103). Subgroup analyses revealed no significant differences in PFS or OS between standard and reduced doses for Ademaciclib and Ribociclib, while Palbociclib at standard dose showed superior PFS (21.9 vs. 12.7 months, p = 0.029) and OS (50.5 vs. 28.6 months, p = 0.026). The incidence of Grade 2–4 AEs was higher in the standard-dose group (74.2% vs. 56.8%, p = 0.044). Conclusions: Dose reduction of CDK4/6 inhibitors, particularly Ademaciclib and Ribociclib, is a viable option in elderly patients, maintaining comparable OS outcomes to standard dosing while reducing the risk of adverse events. Palbociclib at standard dose may offer superior outcomes. These findings support personalized dosing strategies to optimize efficacy and tolerability in frail or elderly patients. Full article
(This article belongs to the Special Issue Innovations and Advances in Breast Cancer Research and Treatment)
►▼ Show Figures

Figure 1

14 pages, 909 KiB  
Article
Health-Related Quality of Life and Associated Comorbidities in Community-Dwelling Women with Breast Cancer
by Dong Kee Jang, Hyung Seok Nam, Jieun Kim and Yeo Hyung Kim
J. Clin. Med. 2024, 13(17), 5321; https://doi.org/10.3390/jcm13175321 - 8 Sep 2024
Viewed by 1548
Abstract
Objective: With advancements in treatment, the increasing number of women with breast cancer has led to a growing focus on enhancing their well-being by understanding health-related quality of life (HRQoL). This study aimed to investigate the association between comorbidities and HRQoL in [...] Read more.
Objective: With advancements in treatment, the increasing number of women with breast cancer has led to a growing focus on enhancing their well-being by understanding health-related quality of life (HRQoL). This study aimed to investigate the association between comorbidities and HRQoL in middle-aged and older community-dwelling Korean women with breast cancer. Methods: Data from the Sixth, Seventh, and Eighth Korea National Health and Nutrition Examination Surveys between 2014 and 2020 were used to analyze 12,218 women aged ≥50 years (244 women with breast cancer vs. 11,974 women without breast cancer). HRQoL was assessed using the EQ-5D-3L tool and the EQ-5D index. Associations between comorbidities (arthritis, depression, hypertension, diabetes, and cardiovascular disease) and HRQoL were examined. Results: Among women with breast cancer, arthritis was associated with problems in mobility (OR, 3.24; 95% CI, 1.39–7.53) and pain/discomfort (OR, 7.30; 95% CI, 3.62–14.73). Depression was associated with problems in self-care (OR, 7.02; 95% CI, 1.97–25.01), usual activities (OR, 5.73; 95% CI, 1.52–21.59), pain/discomfort (OR, 5.58; 95% CI, 1.49–20.87), and anxiety/depression (OR, 3.81; 95% CI, 1.14–12.72). Arthritis and depression were also considerably associated with overall HRQoL, as measured by the EQ-5D index. Hypertension, diabetes, and cardiovascular disease were not independently associated with HRQoL. Conclusions: Arthritis and depression were markedly associated with HRQoL in middle-aged and older women in the community who suffer from breast cancer. Public health interventions that focus on managing these comorbidities can enhance the well-being of women with breast cancer. Full article
(This article belongs to the Special Issue Innovations and Advances in Breast Cancer Research and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop